Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
NCT ID: NCT00578435
Last Updated: 2008-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
25 participants
INTERVENTIONAL
1994-01-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be conditioned for transplantation with cyclophosphamide (50 mg/kg/day x 4 days), and busulfan \[(if \< 4 years of age 1 mg/kg 4 times per day x 4 days), (if \> 4 years of age 0.8 mg/kg 4 times per day x 4 days)\]. Patients will receive Methotrexate \& Cyclosporin-A for prophylaxis against GvHD and GCSF to promote engraftment.
The preferred source of stem cells from related HLA-matched related donors will be unmodified bone marrow stem cells.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Busulfan, Cyclophosphamide, BMD
Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Neurologic event (stroke or hemorrhage).
* Abnormal cerebral MRI scan and cerebral arteriogram or MRI angiographic study (MRA) and impaired neuropsychologic testing.
* Recurrent acute chest syndrome (\> 2 episodes)
* Stage I-II sickle chronic lung disease
* Sickle cell nephropathy (moderate or severe proteinuria or GFR 30-50% of predicted for age.
* Major visual impairment in at least one eye with bilateral proliferative retinopathy.
* Osteonecrosis of multiple bones
* Chronic debilitating pain secondary to vasoocclusive crisis (\>= 3 episodes per year for \>= 3 years) Recurrent priapism
* Allo-immunization with the development of antibodies following chronic transfusion therapy
* Patients with HOMOZYGOUS SICKLE CELL ANEMIA or SICKLE/BETA THALASSEMIA with the following criteria will be considered for accrual on this protocol
* Patients \< 2 years with high WBC counts and/or \>1 episode of dactylitis and/or a Hgb \< 7 g/dl
* History of death from sickle cell disease in sibship of patient
* Patients with BETA-THALASSEMIA MAJOR with Lucarelli class 1 or 2 risk status i.e with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor chelation therapy
* Patients with DIAMOND-BLACKFAN ANEMIA who have failed conventional therapy.
* Patients must have an HLA-compatible related donor. The donor must be healthy and able to undergo general anesthesia. Donors with heterozygous sickle cell anemia (hemoglobin AS) or with heterozygous thalassemia are acceptable donors.
* At the time of referral for transplantation, patients must be in good clinical condition without any evidence of infections and a Karnofsky or Lansky pediatric performance scale \> 70%
* Each patient and donor must be willing to participate as a research subject and must sign an informed consent form after having been advised as to the nature and risk of the study prior to entering the protocol. Parents or legal guardians of patients who are minor will sign the consent form after being advised of the nature and risks of the study
Exclusion Criteria
* Patients with severe major organ dysfunction:
* Patients with severe renal impairment. This will be determined by a creatinine clearance \< 70 ml/min/1.73 m2 (or serum creatinine \> 1.5 x Normal) or by a glomerular filtration rate \< 30% of predicted normal for age
* Inadequate cardiac function as determined by fractional shortening \< 28% on echocardiogram, and/or ejection fraction of \< 50% on echocardiogram or RNCA.
* Patients with FS of 23-28% who show an increase in FS in response to stress on the supine bicycle ergometer are eligible
* Severe residual functional neurologic impairment
* Stage III-IV sickle chronic lung disease
* Pregnant or lactating women are excluded
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Memorial Sloan-Kettering Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Farid Boulad, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan-Kettering web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
94-005
Identifier Type: -
Identifier Source: org_study_id